Published December 11, 2024
| Version v1
Journal article
Open
Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunity
Description
Here, we show that vitamin E succinate (VES) acts as a degrader for the m6A RNA demethylase fat mass and obesity-associated protein (FTO), thus suppressing tumor growth and resistance to immunotherapy. FTO is ubiquitinated by its E3 ligase DTX2, followed by UFD1 recruitment and subsequent degradation in the proteasome. VES binds to FTO and DTX2, leading to enhanced FTO–DTX2 interaction, FTO ubiquitination, and degradation in FTO-dependent tumor cells. VES suppressed tumor growth and enhanced antitumor immunity and response to immunotherapy in vivo in mouse models. Genetic FTO knockdown or VES treatment increased m6A methylation in the LIF (Leukemia Inhibitory Factor) gene and decreased LIF mRNA decay, and thus sensitized melanoma cells to T cell–mediated cytotoxicity. Taken together, our findings reveal the underlying molecular mechanism for FTO protein degradation and identify a dietary degrader for FTO that inhibits tumor growth and overcomes immunotherapy resistance.
Data availability
RNA seq data have been deposited in GEO [RNA sequencing data are accessible at the GEO repository, under accession number GSE250332 (67). All the software and packages used in this article are publicly available.Files
cui-et-al-2024-targeting-dtx2-ufd1-mediated-fto-degradation-to-regulate-antitumor-immunity.pdf
Files
(9.0 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:9b297fb48fa7bfee4e49b4780a1c3839
|
6.2 MB | Preview Download |
|
Article md5:51efacf87650f79ab412c6661685a0e1 |
2.8 MB | Preview Download |
Additional details
Identifiers
- DOI
- 10.1073/pnas.2407910121
- Other
- oai:uchicago.tind.io:14247
Funding
- Human Tissue Resource Center
- SCR_019199
- Cytometry and Antibody Technology
- SCR_017760
- National Institutes of Health
- ES031693
- National Institutes of Health
- ES031534
- University of Chicago
- CA014599
- CACHET
- ES027792
- University of Chicago
- Friends of Dermatology Endowment Fund